The European results of the first-in-human trial of Vascular Dynamics’ MobiusHD implant indicate that the device is associated with a reduction in 24-hour ambulatory systolic blood pressure of 21mmHg from baseline at six months after implantation in patients with resistant hypertension. The study was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain) and published in The Lancet.
The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer) 2.5mg twice daily, plus aspirin 100mg once daily, is associated with a 24% relative risk reduction in cardiovascular death compared with aspirin 100mg once daily alone in patients with coronary artery disease and those with peripheral arterial disease.
Philips and HeartFlow have announced that they have entered into a collaboration agreement with the goal of improving access to diagnostic and planning tools for interventional cardiologists evaluating and treating patients with suspected coronary artery disease. A press release reports that under the agreement, Philips will promote the use of the HeartFlow FFRct analysis in conjunction with Philips’ advanced catheters for imaging and assessing measurements of coronary arteries.
A new subanalysis from the phase III PEGASUS-TIMI 54 trial, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), indicates that 60mg twice daily ticagrelor (Brilinta, AstraZeneca) is associated with a 29% risk reduction in cardiovascular death (p=0.0041)—compared with placebo—in patients taking low-dose aspirin who are still at high risk of an atherothrombotic event.
During a late-breaking science session at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), Pim Tonino (Heart center Catharina Hospital, Eindhoven, the Netherlands) reported that outcomes with a titanium-nitride-oxide coated stent (Optimax, Hexacath) is non-inferior to those of a everolimus-eluting stent with a biodegradable polymer (Synergy, Boston Scientific) in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI).
The SYNTAX II study has found that percutaneous coronary intervention (PCI) using state-of-the-art techniques—including physiological assessment and a new-generation drug-eluting stent—significantly reduces the rate of major adverse cerebrovascular cardiac events (MACCE) in patients with de novo three-vessel disease compared with the PCI strategy used in the original SYNTAX trial. There are also indications that this best-practice strategy, known as the SYNTAX-II strategy, is non-inferior to coronary artery bypass grafting (CABG) in matched patients.
Results from SPYRAL HTN-OFF MED indicate that renal denervation, compared with a sham procedure, significantly reduces blood pressure in patients with hypertension who are not receiving antihypertensive treatment. A previous study found that renal denervation did not significantly reduce blood pressure in patients with resistant hypertension.
The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim)—and not aspirin—and a P2Y12 inhibitor is associated with a significant reduction in major bleeding, compared with conventional triple therapy, in patients with atrial fibrillation who have undergone percutaneous coronary intervention (PCI). A previous trial, PIONEER AF-PCI, reported similar findings with another non-vitamin K antagonist oral anticoagulant (rivaroxaban, Xarelto, Bayer).
BioStable Science & Engineering has received US Food and Drug Administration (FDA) market clearance for the HAART 200 aortic annuloplasty device. This is the first and only annuloplasty device designed specifically for bicuspid aortic valve repair.
New research has discovered a potential means to trigger damaged heart cells to self-heal. For the first time, researchers have identified a long non-coding ribonucleic acid (ncRNA) that regulates genes controlling the ability of heart cells to undergo repair or regeneration. This novel RNA, which researchers have named “Singheart”, may be targeted for treating heart failure in the future.
Physicians identified a majority of patients with advanced heart failure as at high risk for transplant, left ventricular assist device (LVAD) or death while few of those patients considered themselves to be at high risk, according to a study published today in JACC: Heart Failure.
Four Blue Cross Shield companies have issued positive medical policies for the HeartFlows FFRct Analysis. Horizon Blue Cross Blue Shield of New Jersey, Blue Cross Blue Shield of Arizona, Blue Cross of Idaho and Blue Cross Blue Shield of Kansas City have each issued a positive medical policy for the technology.
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published in the European Journal of Preventive Cardiology.
LivaNova’s Perceval sutureless aortic heart valve has received approval from the US Centers for Medicare and Medicaid Services (CMS) for a New Technology Add-on Payment (NTAP).
4C Medical Technologies has announced that its medical device therapy for mitral regurgitation was featured in the Innovation Summit at Cardiovascular Innovations (CVI) 2017 (2 August, Denver, USA). A press release reports that the company developing the first mitral regurgitation therapy that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos